However, CD8+ tumor infiltration, along with PD-1, Tim-3, and PD-L1 expression also increased following treatment, suggesting that these oncogene-targeted therapies might be limited and should be combined with immunotherapy to achieve long-term responses (77). This evidence concerns the gene CD8A and neoplasm.